You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍逆升 康方、藥明系、金斯瑞及信達生物漲7.5%-15%
白宮首席醫療顧問福奇上周指,美國正在擺脫新冠疫情全面流行,疫苗股昨晚跌幅遠超美股,尤其是BioNTech(BNTX.US)及莫德納(MRNA.US)分別挫9.6%及11.7%,輝瑞(PFE.US)跌1.9%。 然而,本港醫藥股今天普遍逆市反彈。其中信達生物(01801.HK)與馴鹿醫療共同開發用於治療復發/難治性多發性骨髓瘤藥獲美國FDA孤兒藥資格,該股終止兩連跌,由近兩年低位重越10天線(31.8元),最高見33.2元,現報33.05元,急漲15%,成交有1,516萬股。 日前公布子公司達成兩大里程碑合作協議並獲對方支付共5,000萬美元付款的金斯瑞生物(01548.HK)兩連升,今早低開2.6%報24.05元,最低見24元獲承接,掉頭高見27.4元,現報27.35元,續升11%。 康方生物-B(09926.HK)終止兩連跌,股價由上市低位反彈重越10天線(19.97元),最高見20.35元,現報20.1元,回升7.5%,成交已有398萬股。 藍籌藥明生物(02269.HK)終止五連跌,股價由約年半收市低位反彈,最高見60.95元,現報60.4元,回升7.9%;其母企藥明康德(02359.HK)繼昨天止跌回升後,今早股價高見101.3元(暫受制10天線101.75元),現報100元,續漲10%。 百濟神州(06160.HK)終止兩連跌,股價挑戰10天線(128.65元),最高見129.4元,現報128.1元,回升6.1%。四環醫藥(00460.HK)高見1.73元,創逾兩個月高,現報1.7元,回升6.3%。開拓藥業-B(09939.HK)低開報11.82元獲承接,掉頭高見13.12元,現報12.6元,續升4.1%。歌禮製藥-B(01672.HK)反覆續升2%報4.62元。 復星醫藥(02196.HK)子公司抗結核藥獲國家藥監局藥品註冊申請審理,股價終止兩連跌曾重越10天線(31.5元),最高見31.6元,現報31.35元,回升1.8%。威高股份(01066.HK)今早低開報9.54元獲承接,掉頭高見10.1元,現報9.99元,倒升1.7%。康希諾生物-B(06185.HK)反覆兩連彈,高低分別見130.6元及124元,現報129元,反覆續彈1.4%。 恆指及國指現報24,383及8,539,續跌0.7%及0.9%,總成交額523億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account